Arginine

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
torsdag, maj 9, 2024
Hep G2, Enzyme replacement therapy, Hepatocyte, Cell, Exosome, Partnership, Vaccine, Urea, Therapy, Liver, Gene family, Annual general meeting, Biotechnology, SAN, Arginine

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that an abstract featuring new preclinical data highlighting the therapeutic potential of its StealthX™ exosome platform technology has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place in Baltimore, Maryland from May 7–11, 2024. The findings highlight a potential exosome-based approach for the treatment of arginase-1 deficiency (ARG1-D), a rare genetic metabolic disease characterized by complete or partial lack of the enzyme arginase in the liver and red blood cells.

Key Points: 
  • The findings highlight a potential exosome-based approach for the treatment of arginase-1 deficiency (ARG1-D), a rare genetic metabolic disease characterized by complete or partial lack of the enzyme arginase in the liver and red blood cells.
  • “The findings from this preclinical study have further characterized our StealthX™ exosome platform and provide a novel approach for exosome-based enzyme-replacement therapies which aim to replace a deficient or absent enzyme,” said Linda Marbán, Ph.D., Capricor’s chief executive officer.
  • “We believe our StealthX™ platform provides an opportunity with potentially broad applications and our data continues to support the concept of exosomes as a suitable delivery vehicle for a variety of payloads.
  • Results showed the Arg1-exosomes were enzymatically active and able to convert arginine into urea in vitro.

Peanuts and Peanut Butter Support Women's Health

Retrieved on: 
onsdag, maj 8, 2024
Snack, Mortality, Adolescence, Nutrition, Risk, Mineral, Nutrition and Cancer, PMID, Grain boundary strengthening, Sport, Niacin, Death, American Academy of Pediatrics, PubMed, Parent, Water, INT, Choline, Food, Mother, Neurosurgery, Control, Cancer, Phytosterol, Journal, Peanut, American Heart Association, Deficit spending, Alzheimer's disease, Cyrus the Great, American Academy, Brain, Iron, Randomized controlled trial, Cardiovascular disease, Dementia, Arginine, Zinc, Vitamin, Infant, Infection, Choking, Meta-analysis, Consumer, Health, Research, Taste, Dicarboxylic acid, Food industry, Exercise, Sterling, Lung, Pediatrics, Multimedia, Fruit, Breast milk, Pinterest, Meal, Stomach, Habit, Disease, PubMed Central, Nut, General Population (album), Growth, Dietary supplement

To help women protect their health, The Peanut Institute is sharing information on the benefits that regular consumption of peanuts and peanut butter deliver to females at every stage of life.

Key Points: 
  • To help women protect their health, The Peanut Institute is sharing information on the benefits that regular consumption of peanuts and peanut butter deliver to females at every stage of life.
  • Initially, parents can thin a very small amount of peanut butter or peanut powder with water and mix it into rice cereal.
  • "For example, offering healthy snacks like fresh veggies or fruit paired with peanut butter or peanuts is a great option.
  • For more health news and tasty recipes that include peanuts and peanut butter, visit PeanutInstitute.com or follow Facebook , Twitter , Instagram , LinkedIn and Pinterest .

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
söndag, april 7, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Toxicity, TP53, Patient, Lung, Arginine, AACR, Cholangiocarcinoma, Therapy, TRAC, Pancreas, CRISPR, TCR, Vaccine

Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.

Key Points: 
  • Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.
  • “We are also proud to present preclinical data from our cell therapy targeting KRAS G12D, which highlights the promising potential of our proprietary non-viral knock-in THRIVE™ platform.
  • The study supports the planned clinical investigation of the novel KRAS G12D mutant TCR-engineered CD4+ and CD8+ T cell therapy in 2024.
  • These data support the planned clinical development of a novel non-viral TRAC-knocked-in T cell therapy for the treatment of p53 R175H-mutant solid tumors.

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
onsdag, mars 6, 2024
WBC, WRN, Lung cancer, RNA, Malignancy, Microsatellite instability, Proteome, Intellectual property, MMR, MPN, Glioblastoma, Neoplasm, Splenomegaly, DMPK, Phosphorylation, HDAC, STAT5, RNA-Seq, WES, Standard of care, Therapy, RecQ helicase, Phenotype, Ruxolitinib, DNA, DNA repair, Pancreatic serous cystadenoma, CDKN2A, Cancer, CRC, PIM, Arginine, MTA, Abstract, PDC, MTAP, Colorectal cancer, CRISPR, PV, MF, MSI-H, Cell, JAK, DNA mismatch repair, Medicine, Patient, Gene, PRMT5, Haematopoiesis, Mesothelioma, Pharmaceutical industry

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

Every Cure to Receive $48.3M from ARPA-H to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing

Retrieved on: 
onsdag, februari 28, 2024
Master of Science, ARPA, Chan Zuckerberg Initiative, ALS, Extension, AI, MD, Intelligence, Physician, FDA, Pennsylvania State University, Flagship Pioneering, DARPA, Drug discovery, Government, MBA, University, White, Spectrum, Entrepreneurship, Semaglutide, Arginine, Organization, Associate, Sickle cell disease, Patient, Disease, NCATS, MATRIX, Research, Pharmaceutical industry

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Every Cure, a nonprofit on a mission to save lives by repurposing existing medicines, announced today significant funding from the Advanced Research Projects Agency for Health (ARPA-H). The three-year, $48.3 million contract was unveiled at the White House this evening and represents a substantial federal investment in drug repurposing. It will accelerate Every Cure's mission to unlock the full potential of existing drugs to treat more diseases through the development of an AI-powered platform, called ML/AI-enabled Therapeutic Repurposing In eXtended uses (MATRIX).

Key Points: 
  • The three-year, $48.3 million contract was unveiled at the White House this evening and represents a substantial federal investment in drug repurposing.
  • "I'm alive and in remission from my rare disease thanks to a repurposed drug that I discovered.
  • "Through Every Cure, we are working tirelessly to unlock the full potential of FDA-approved drugs to treat many more diseases.
  • The ARPA-H funding will enable Every Cure to:
    Develop an open-source drug repurposing database.

MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITY

Retrieved on: 
tisdag, februari 13, 2024
RDT, Entrepreneurship, Sildenafil, SF, Arginine, Oxytocin, Music

Dallas, Texas, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a men’s health & wellness company, will offer a free one-year supply of its “Mango” erectile dysfunction product to the San Francisco players and coaches to raise spirits following Sunday’s Big Game loss, ensuring they can still perform in the bedroom after losing on the field.

Key Points: 
  • Players and coaches of the SF-based team can send redemption inquiries to [email protected] with subject line “The Big Game” for access to their one-year supply of Mango.
  • MangoRx’s Tadalafil and Sildenafil based Mango ED products are compounded with both Oxytocin and L-Arginine in a tasty Mango-flavored, rapid dissolve tablet (RDT).
  • “With a defeating loss, the disappointment can linger into the bedroom but we want to make sure San Francisco players and fans can still score after the game.
  • At MangoRx, we want to help take the pressure off and focus on good times ahead,” says Jacob Cohen, Co-Founder and CEO of MangoRx.

MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS

Retrieved on: 
tisdag, februari 6, 2024
Life, Arginine, Erectile dysfunction, Sadness, Oxytocin, Running, Sildenafil, Marketing, Radio, Entrepreneurship, Depression, Bedroom, Stage fright, Sport, RDT, Nursing

Dallas, Texas, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (“GROW”) and erectile dysfunction (“ED”) drug (“Mango”), announces that regardless of who loses the Big Game this Sunday, they are prepared to offer a free one-year supply of its Mango ED products for the entire losing team, ensuring they still get sacked after the game.

Key Points: 
  • This code will be available to fans following the results of the Big Game.
  • MangoRx’s signature ED product Mango (think "Man, Go) is a uniquely formulated drug which leverages the active ingredients found in either Cialis™ (Tadalafil) or Viagra™ (Sildenafil).
  • MangoRx’s Tadalafil and Sildenafil based Mango ED products are compounded with both Oxytocin and L-Arginine in a tasty Mango-flavored, rapid dissolve tablet (RDT).
  • “Just because your team doesn’t perform on the field, doesn’t mean the fans shouldn’t be able to score.

Foundation Fighting Blindness Launches GYROS, a Natural History Study for People with Gyrate Atrophy

Retrieved on: 
tisdag, februari 6, 2024
Paratriathlon, Arginine, Visual impairment, Clinical trial, Wilmer Ophthalmological Institute, FDA, OAT, Associate, Plasma, Human services, Genetic distance, HHS, Government, Diet, Alanine transaminase, Tissue, Nyctalopia, Unitary state, Johns Hopkins University, Patient, Retina, Ornithine aminotransferase deficiency, DRS, Doctor of Philosophy, Research, MHS

COLUMBIA, Md. , Feb. 6, 2024 /PRNewswire/ -- `The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for inherited retinal diseases and dry age-related macular degeneration, is launching a natural history study for people with gyrate atrophy, a rare, vision-robbing inherited retinal disease. The lead investigators for the study are Mandeep S. Singh, MD, PhD, the Andreas C. Dracopoulos Professor of Ophthalmology and Associate Professor of Ophthalmology and Genetic Medicine at the Wilmer Eye Institute and David Valle, MD, Professor of Genetic Medicine and former director of the McKusick-Nathans Department of Genetic Medicine at Johns Hopkins University.

Key Points: 
  • GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.
  • , Feb. 6, 2024 /PRNewswire/ -- `The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for inherited retinal diseases and dry age-related macular degeneration, is launching a natural history study for people with gyrate atrophy, a rare, vision-robbing inherited retinal disease.
  • Known as the Gyrate Atrophy Ocular and Systemic Study (GYROS), the $3.5 million study is informing the design of future clinical trials for gyrate atrophy.
  • Gyrate atrophy is a progressive retinal disease that causes night blindness and loss of peripheral vision, in addition to severe childhood-onset myopia.

Pharmactive's Saffron Extract improves Resilience to Occasional Stress

Retrieved on: 
onsdag, januari 24, 2024
DSM-IV codes, Hypothalamus, Arginine, Iterative method, Pituitary gland, Research, Overalls, Manager, Food, Health, Brain-derived neurotrophic factor, HPA, Hormone, Survival, Communication, History, Nutrient, Anxiety, Pandemic, Human, Gland, Doctor of Philosophy, Rat, Anhedonia, ACTH, Adrenocorticotropic hormone, CRF, Brain, Motivation, Glucocorticoid, BDNF, Depression, Growth

MADRID, Jan. 24, 2024 /PRNewswire/ -- A new in vitro study sheds light to the stress relief effect of saffron (Crocus sativus L). The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.

Key Points: 
  • The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.
  • Results demonstrated significant improvements following repeated oral administration of the extract in stress model animal subjects.
  • The HPA axis is a vital brain signaling system involved in orchestrating responses to stress.
  • We are realizing these extend beyond influencing serotonin expression but actually demonstrates a potential to boost resilience to occasional stress and prevent its detrimental impact on overall mental and physical health."

Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)

Retrieved on: 
måndag, december 4, 2023
Leiomyosarcoma, Survival, Docetaxel, Sarcoma, Disease, SAN, Cancer, Arginine, LMS, Overalls, Patient, Combo

The decision to move forward with this global, Phase 3 trial is based on the positive results of a Phase 2 trial.

Key Points: 
  • The decision to move forward with this global, Phase 3 trial is based on the positive results of a Phase 2 trial.
  • Furthermore, the Phase 2 trial clinically confirmed that lower doses of gemcitabine and docetaxel could be used with ADI-PEG 20, which was predicted by preclinical studies.
  • These lower doses of gemcitabine and docetaxel will be used with ADI-PEG 20 in the Phase 3 trial, while the placebo group will be treated with standard doses of both agents.
  • ADI-PEG 20, an enzyme therapy to starve cancer cells, has emerged as a useful agent across a number of cancers.